May 29, 2026
A DNA sequencing startup will have to rejigger its antitrust lawsuit against Illumina after a California federal judge said it hasn't shown that the industry giant has entered exclusive agreements and hasn't adequately asserted that Illumina priced its offerings below cost, among other failings.